A new chemical tool for exploring the role of the PDE4D isozyme in leukocyte function

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 3, 2006, Pages 718-721

  Chambers, Robert J ^a   Abrams, Kristin ^a   Castleberry, Tessa A ^a   Cheng, John B ^a   Fisher, Douglas A ^a   Kamath, Ajith V ^a   Marfat, Anthony ^a   Nettleton, David O ^a   Pillar, Joann D ^a   Salter, Eben D ^a   Sheils, Alissa L ^a   Shirley, John T ^a   Turner, Claudia R ^a   Umland, John P ^a   Lam, Kelvin T ^a  

^a PFIZER INC   (United States)

Author keywords

Eosinophil; PDE4D; Phosphodiesterase

Indexed keywords

ISOENZYME; NICOTINAMIDE; PHOSPHODIESTERASE; PHOSPHODIESTERASE 4D; PHOSPHODIESTERASE INHIBITOR; ROLIPRAM; UNCLASSIFIED DRUG;

ARTICLE; EOSINOPHIL; HUMAN; HUMAN CELL; LEUKOCYTE FUNCTION; MEDIATOR RELEASE; NEUTROPHIL CHEMOTAXIS; PROTEIN FUNCTION;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; CHEMOTAXIS; EOSINOPHILS; ISOENZYMES; LEUKOCYTES; NIACINAMIDE; PHOSPHODIESTERASE INHIBITORS; ROLIPRAM;

EID: 29544440713     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.10.026     Document Type: Article

References (39)

1. J.A. Beavo Physiol. Rev. 75 1995 725
2. T. Muller, P. Engels, and J.R. Fozard Trends Pharm. Sci. 17 1996 294
3. J.E. Souness, C. Maslen, S. Webber, M. Foster, D. Raeburn, M.N. Palfreyman, M.J. Ashton, and J-A. Karlsson Br. J. Pharmacol. 115 1995 39
4. J. Bousquet, P. Chanez, J.Y. Lacoste, G. Barneon, N. Ghavanian, I. Enander, P. Venge, S. Ahlstedt, J. Simony-Lafontaine, P. Godard, and F.-B. Michel N. Engl. J. Med. 323 1990 1033
5. G. Hansen, S.-L.C. Jin, D.T. Umetsu, and M. Conti Proc. Natl. Acad. Sci. U.S.A. 97 2000 6751
6. C. Mehats, C. Jin, J. Wahlstrom, E. Law, D.T. Umetsu, and M. Conti FASEB J. 17 2003 1831
7. J. Zhu, E. Mix, and W. Winblad CNS Drug Rev. 7 2001 387
8. H. Dyke, and J. Montana Expert Opin. Invest. Drug 11 2002 1
9. R. Hersperger, K. Bray-French, L. Mazzoni, and T. Muller J. Med. Chem. 43 2000 675
10. A. Trifilieff, D. Wyss, C. Walker, L. Mazzoni, and R. Hersperger J. Pharm. Exp. Ther. 301 2002 241
11. R. Hersperger, J. Dawson, and T. Mueller Bioorg. Med. Chem. Lett. 12 2002 233
12. For preparations of PDE2, PDE3, PDE5, PDE8A, PDE8B, PDE9, PDE10, and PDE11 isozymes, see: N. Dickinson, E. Jang, and R. Haslam Biochem. J. 323 1997 371
13. D. Fisher, J. Smith, J. Pillar, S. Denis, and J. Cheng Biochem. Biophys. Res. Commun. 246 1998 570
14. M. Hayashi, K. Matsushima, H. Ohashi, H. Tsunoda, S. Murase, Y. Kawarada, and T. Tanaka Biochem. Biophys. Res. Commun. 250 1998 751
15. D. Fisher, J. Smith, J. Pillar, S. Denis, and J. Cheng J. Biol. Chem. 273 1998 15559
16. K. Fujishige, J. Kotera, and K. Omori Eur. J. Biochem. 266 1999 1118
17. L. Fawcett, R. Baxendale, P. Stacey, C. McGrouther, I. Harrow, S. Soderling, J. Hetman, and J. Beavo Proc. Natl. Acad. Sci. U.S.A. 97 2000 3702
18. ® assay, the format used against these isozymes, see: K. Ilona, M. Stevens, D. Behrens, and K. Oldenburg J. Biomol. Screen. 4 1999 27
19. For the preparation of PDE4A, PDE4B, PDE4C, and PDE4D isozymes and method for evaluating compounds, see: V. Cohan, H. Showell, D. Fisher, C. Pazoles, J. Watson, C. Turner, and J. Cheng J. Pharm. Exp. Ther. 278 1996 1356
20. 2 (9), calcium channel L (DHP, 25) calcium channel L (dilitiazem, 6) calcium channel L (verapamil, 0) calcium channel N (0).
21. M. Grous, S.B. Christensen, M. Burman, L. Cieslinski, L. Huang, T.J. Torphy, and M.S. Barnette Pharm. Rev. Commun. 9 1997 237
22. M. Schichijo, N. Inagaki, M. Kimata, I. Serizawa, H. Saito, and H. Nagai J. Allergy Clin. Immunol. 103 1999 S421
23. P.L.B. Bruijnzeel Int. Arch. Allergy Appl. Immunol. 90 1989 57
24. Cheng, J.; Pillar, J.; Shirley, J. Third International Conference on Cyclic Nucleoside Phosphodiesterases-from Genes to Therapies, Glasgow, Scotland, July 18-21, 1996, Abstract 25.
25. M.W. Verghese, R.T. McConnell, A.B. Strickland, R.C. Goodling, S.A. Stimpson, D.P. Yarnall, J.D. Taylor, and P.J. Furdon J. Pharmacol. Exp. Ther. 272 1995 1313
26. P. Wang, P. Wu, K.M. Ohleth, R.W. Egan, and M.M. Billah Mol. Pharmcol. 56 1999 170
27. C.D. Manning, M. Burman, S.B. Christensen, L.B. Cieslinski, D.M. Essayan, M. Grous, T.J. Torphy, and M.S. Barnette Br. J. Pharmacol. 128 1999 1393
28. S.L. Jin, and M. Conti Proc. Natl. Acad. Sci. U.S.A. 99 2002 7628
29. T. Kaneko, R. Alvarez, I.F. Ueki, and J.A. Nadel Cell. Signal. 7 1995 527
30. L. Harvarth, C.E. McCall, D.A. Bass, and L.C. McPhail J. Immunol. 139 1987 3055
31. S. Lamontagne, E. Meadows, P. Luk, D. Normandin, E. Muise, L. Boulet, D.J. Pon, A. Robichaud, G.S. Robertson, K.M. Metters, and F. Nantel Brain Res. 920 2001 84
32. A. Robichaud, P.B. Stamatiou, S.-L.C. Jin, N. Lachance, D. MacDonald, F. Laliberte, S. Liu, Z. Huang, M. Conti, and C.-C. Chan J. Clin. Invest. 110 2002 1045
33. -6 cm/s, turbidimetric solubility at pH 7 >65 μg/ml.
34. C.R. Turner, C.J. Andresen, W.B. Smith, and J.W. Watson Am. J. Respir. Crit. Care Med. 149 1994 1153
35. Nicotinamide (2) was formulated in 25% EtOH/75% HFA MDI canisters. Animals were dosed for 15 min prior to antigen challenge and at 4 h post antigen challenge. Cell infiltration was determined at 24 h post antigen challenge.
36. P. Wang, P. Wu, K.M. Ohleth, R.W. Egan, and M.M. Billah Mol. Pharmacol. 56 1999 170
37. F. Vinick, N. Saccomano, B. Koe, J. Nielsen, I. Williams, P. Thadeio, S. Jung, M. Meltz, J. Johnson, L. Lebel, L. Russo, and D. Helweg J. Med. Chem. 34 1991 86
38. F. Blicke, and J. Burckhalter J. Am. Chem. Soc. 64 1942 477
39. M. Burk, Y. Wang, and J. Lee J. Am. Chem. Soc. 118 1996 5142 see supporting information.